Onyx Scientific reported a 45% growth in its solid formulation-related revenues this year, driven by early stage drug development projects. The company’s alliance with Molecular Profiles has also contributed to growth, with increased activity in the biotechnology and early stage clinical sector.   Denise Bowser, commercial director at Onyx Scientific, said, “Over the past few years, we have proudly become a real specialist in solid-state chemistry focused on providing detailed investigation to c...